Significant impact of transient deterioration of renal function on dosimetry in PRRT

Annals of Nuclear Medicine

Volumn 27, Issue 1, 2013, Pages 74-77

  Van Binnebeek, Sofie ^a   Baete, Kristof ^a   Terwinghe, Christelle ^a   Vanbilloen, Bert ^a   Haustermans, Karin ^a   Mortelmans, Luc ^a   Borbath, Ivan ^b   Van Cutsem, Eric ^a   Verslype, Chris ^a   Mottaghy, Felix M ^c   Verbruggen, Alfons ^d   Deroose, Christophe M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Dosimetry; Kidney function; Peptide receptor radionuclide therapy; Yttrium 90

Indexed keywords

ANGIOPEPTIN; CREATININE; LUTETIUM 177; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OXYCODONE; PENTETREOTIDE IN 111; TETRAXETAN; YTTRIUM 90;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGED; ARTICLE; BACKACHE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIARRHEA; DOSIMETRY; FLUSHING; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY MEDULLA; KIDNEY TUBULE ABSORPTION; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; PERITONEUM METASTASIS; PRIORITY JOURNAL; SMALL INTESTINE TUMOR;

AGED; HUMANS; INTESTINAL NEOPLASMS; KIDNEY; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; ORGANS AT RISK; RADIOMETRY; RADIOTHERAPY; RECEPTORS, PEPTIDE; TIME FACTORS;

EID: 84872678666     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0651-y     Document Type: Article

References (11)

1. Bodei L, Cremonesi M, Grana CM, Chinol M, Baio SM, Severi S, et al. Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S93-102. Epub 2012/03/06.
2. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):62S-6S. Epub 2005/01/18.
3. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43(5):610-6. Epub 2002/05/08.
4. De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med. 2004;45(7):1168-71. Epub 2004/07/06.
5. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(Suppl 1):99S-106S. Epub 2005/01/18.
6. de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med. 2002;43(5):617-20. Epub 2002/05/08.
7. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31(7):1038-46. Epub 2004/05/20.
8. Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35(3):1123-34. Epub 2008/04/15.
9. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol. 2004;22(13):2724-9. Epub 2004/07/01.
10. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847-56. Epub 2008/04/23.
11. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416-23. Epub 2011/05/11.